Pharmaceuticals

Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting

Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...

2024-04-24 22:10 710

Future Health highlights greater access to treatment for Mental Health Month

SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll has highlighted an alarming trend: a staggering 90% of Americans feel we are in a mental health crisis. While Mental Health Month in May seeks to build ...

2024-04-24 22:00 577

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved inEurope Conditional marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /PR...

2024-04-24 15:00 908

Samsung Biologics Reports First Quarter 2024 Financial Results

* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...

2024-04-24 14:45 767

RELIFE BY A. MENARINI CHAMPIONS PERSONAL CHOICE IN AESTHETIC TREATMENTS, ENCOURAGING SELF-CARE AND SELF-LOVE

-       The choice is the individual's hand to treat oneself with love and care, where judgments and negative opinions have no place in personal beauty journeys. KUALA LUMPUR, Malaysia, April 24, 2024 /PRNewswire/ -- RELIFE, the dermatology and aesthetic medicine division of A. Menarini, a wholl...

2024-04-24 10:00 888

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...

2024-04-24 09:27 721

OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...

2024-04-23 18:37 1131

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...

2024-04-23 14:54 818

Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing

SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed  Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...

2024-04-23 08:00 824

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...

2024-04-23 07:25 1300

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial

Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW)  announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD)....

2024-04-22 20:30 754

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

SUZHOU, China, April 21, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced thatthe China phase II clinical trial (the "Phase II Clinical Trial") of i...

2024-04-22 09:53 1637

Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards

SINGAPORE, April 18, 2024 /PRNewswire/ -- Juniper Biologics

2024-04-22 09:00 1007

Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards

SINGAPORE, April 22, 2024 /PRNewswire/ -- Juniper Biologics

2024-04-22 09:00 1112

BGI Genomics Leads Innovation with Inaugural Clinical Lab in Uruguay

Cutting-edge facility to serve as a beacon for preventive medicine in Latin America MONTEVIDEO, Uruguay, April 22, 2024 /PRNewswire/ -- BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory atUruguay's Parque de las Ciencias free trad...

2024-04-22 08:27 1113

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

TAMPA, Fla., April 20, 2024 /PRNewswire/ -- Concept Medical , a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" usingMagicTouch

2024-04-20 01:11 1788

Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success

* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...

2024-04-19 21:00 2340

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-19 19:00 3579

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a mult...

2024-04-19 19:00 1800

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a...

2024-04-18 21:00 1851
12345 ... 293